QPPV.COM KNOWLEDGE ASSESSMENT

Professional Knowledge Assessment: Trastuzumab Emtansine Classification, Mechanism, Safety and Pharmacovigilance

Test your understanding of the concepts covered by Trastuzumab Emtansine: Classification, History, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Why should a haemorrhage report not be assessed solely by reviewing the platelet count?

Bleeding cannot occur in patients receiving trastuzumab emtansine Haemorrhage may occur with or without severe thrombocytopenia and requires assessment of site, severity, platelet trajectory, coagulation and interacting medicines Platelet counts are irrelevant to bleeding assessment The only meaningful determinant of haemorrhage is the patient's HER2 status

Question 2 of 10 Which feature best supports a payload-associated explanation for peripheral neuropathy in a trastuzumab emtansine case?

The patient has HER2-positive disease, without any need to assess symptom characteristics A new or worsening microtubule-related sensory or motor neuropathy temporally associated with treatment, assessed against prior taxane neuropathy Neuropathy occurs only if the patient also develops thrombocytopenia The symptom is automatically unrelated if it improves after treatment modification

Question 3 of 10 Which situation could represent a new safety question even if the adverse event is already a labelled risk?

A known event occurring in a patient, with no additional information relevant to pattern or severity A change in latency, severity, reversibility, risk factors or outcome for the known event Any event that is reported using a standard MedDRA preferred term A case in which the product identity has been confirmed and no clinical details are available

Question 4 of 10 Which approach is most appropriate for a pregnancy exposure involving trastuzumab emtansine?

Record only the date of the first dose because pregnancy outcome is unrelated to exposure timing Reconstruct conception timing, dose dates, gestational age, co-exposures, fetal monitoring and pregnancy or neonatal outcome Assess only whether the mother experienced thrombocytopenia Close the case once exposure has been confirmed, without follow-up of the pregnancy

Question 5 of 10 Which finding would most strongly support a clinically important hepatic safety concern rather than an isolated laboratory abnormality?

A single mildly increased ALT with no symptoms, no bilirubin increase and no follow-up data Repeated enzyme abnormalities accompanied by bilirubin or synthetic-function changes, structural findings or portal-hypertension features A normal ALT obtained before the first dose A transient platelet decrease without any hepatic findings

Question 6 of 10 Which statement best describes the relationship between thrombocytopenia and DM1 in trastuzumab emtansine treatment?

Thrombocytopenia is biologically implausible because the antibody selectively targets tumour cells DM1-containing catabolites and effects on megakaryocyte biology provide a plausible payload-associated explanation Thrombocytopenia can only be caused by prior anthracycline exposure The event is expected to occur only when free DM1 is deliberately administered intravenously

Question 7 of 10 What is the primary role of the trastuzumab-derived antibody in trastuzumab emtansine?

To cleave the linker in the bloodstream and release free DM1 To provide HER2 recognition and facilitate delivery of the conjugate to HER2-expressing cells To prevent all uptake of the conjugate by normal tissues To replace the microtubule-inhibitory activity of DM1

Question 8 of 10 Which additional information is most important for distinguishing transient liver enzyme elevation from clinically important liver injury in a trastuzumab emtansine case?

Only the patient's tumour HER2 score Bilirubin, INR, imaging, hepatic metastases, portal-hypertension features and relevant co-exposures Only whether the patient experienced an infusion reaction during the same cycle The antibody isotype without any laboratory or clinical information

Question 9 of 10 Which data are most useful for distinguishing an acute infusion reaction from immediate hypersensitivity?

The patient's tumour stage alone Timing from infusion start, clinical phenotype, vital signs, interventions, interruption and any rechallenge outcome Only the total cumulative dose received during the treatment course Only the presence or absence of thrombocytopenia

Question 10 of 10 Which case-context feature is particularly important when comparing thrombocytopenia reports across trastuzumab emtansine populations?

Whether the patient has ever received any monoclonal antibody, regardless of disease setting Disease setting, prior therapy, baseline marrow reserve and treatment intent Only the patient's HER2 test result, because other factors do not influence interpretation Only whether the event was reported using a preferred MedDRA term

Professional Knowledge Assessment: Trastuzumab Emtansine Classification, Mechanism, Safety and Pharmacovigilance

Cookie Settings